Allezoe Medical Holdings, Inc. (ALZM) is a holding company focused on acquiring the most high-quality and in demand medical products, solutions and services.
We believe it is possible to create value for shareholders as well as recipients of healthcare services at the same time, and we do so through acquisition and support of technologies that improve healthcare delivery and address the most urgent health issues facing the world today. Whether through diagnosis, treatment, or medical research itself, Allezoe is interested in companies that are making a striking difference in the healthcare system through technology and treatments for health issues that affect large populations.
Allezoe Medical Holdings’ subsidiary, SureScreen Medical, Inc., has signed an exclusive license to develop and market a breakthrough medical technology that will, potentially, revolutionize the diagnosis and treatment of Human Papillomavirus (HPV), Bovine Papillomavirus (BPV), and potentially cervical cancer. HPV is the most common sexually transmitted infection -- there are more than 40 types -- and most people who become infected do not know they have it, leading to further spread. Approximately 20 million Americans are infected with HPV and it is estimated that 5.5 million people will contract it each year.
The potential impact of the SureScreen© technology is particularly important with regard to cervical cancer, the second most common cancer in women. Cervical cancer can be prevented with the right technologies and treatments. SureScreen’s© See-&-Treat© technology aims to replace the existing practice of testing a patient for HPV and requiring her to return to a healthcare provider for the results and, if necessary, treatment with a single-visit solution. Especially in third-world regions, diagnosing and treating HPV in women in a single visit can significantly raise the level of treatment and, potentially, severely reduce cervical cancer rates.